Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Johnson & Johnson
Sort By
Newest First
1 / 2
1 / 2
Sign in
Pediatric
Johnson & Johnson Seeks U.S. FDA Approval for First Pediatric Indications for TREMFYA®
Johnson & Johnson
PR-12-24-NI-126
Dec 03, 2024
Large Molecule
Johnson & Johnson Submits Applications Seeking Approval as Subcutaneous Monotherapy for High-Risk moldering Multiple Myeloma
Johnson & Johnson
PR-10-24-NI-88
Nov 08, 2024
Clinical Trials
TREMFYA is the first and only IL-23 inhibitor to demonstrate robust results with regimen in both induction and maintenance
Johnson & Johnson
PR-10-24-NI-64
Oct 28, 2024
Clinical Trail
TALVEY and DARZALEX FASPRO shows deep and durable responses in patients with relapsed or refractory multiple myeloma
Johnson & Johnson
PR-09-24-NI-21
Sep 27, 2024
Clinical Trails
TALVEY and TECVAYLI suggests high response rates in triple-class refractory patients with relapsed or refractory multiple myeloma
Johnson & Johnson
PR-09-24-NI-20
Sep 27, 2024
COVID-19 Trials
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
Johnson & Johnson
PR-M09-20-27
Sep 24, 2020
Vaccine
European Commission Concludes Further Talks to Secure J&J COVID-19 Vaccine
Johnson & Johnson
PR-M08-20-NI-24
Aug 14, 2020
COVID-19 Vaccine
Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
Janssen Pharmaceutical Companies
PR-M08-20-NI-11-1359
Aug 06, 2020
HIV Prevention
Johnson & Johnson and Its Partners Mark a Milestone in the Quest for a Global Preventive HIV Vaccine with the Imbokodo Study
Johnson & Johnson
PR-M07-20-NI-026
Jul 16, 2020
COVID-19 Vaccine Manufacturing
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate
Emergent Biosolutions
PR-M07-20-NI-007
Jul 07, 2020
COVID-19 Vaccine
Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate
Catalent
PR-M04-20-NI-044-1583
Apr 30, 2020
Vaccine
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19
Johnson & Johnson
PR-M03-20-NI-045
Mar 31, 2020
Coronavirus
J&J Cites Lack of Evidence for HIV Treatment Against COVID-19
Johnson & Johnson
PR-M03-20-NI-026
Mar 17, 2020
Collaboration
Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine
Johnson & Johnson
PR-M02-20-NI-017
Feb 14, 2020
Depression
Trump Urges VA to Use Spravato
Nice Insight
PAO-M00-19-NI-007
Sep 04, 2019
Opioid Crisis
J&J Awaits Judge’s Decision in Lawsuit Filed by Oklahoma Over the Opioid Crisis
Nice Insight
PAO-M07-19-NI-021
Jul 22, 2019
FDA Approval
FDA Grants Additional Myeloma Approval to J&J’s Darzalex
Emilie Branch
Pharma's Almanac
PAO-M07-19-NI-014
Jul 10, 2019
Opioid Crisis
Oklahoma vs. Johnson & Johnson Opioid Crisis Trial
Nice Insight
PAO-M06-19-NI-006
Jun 13, 2019
Oncology
FDA Will Use Real-Time Oncology Review for Prostate Cancer Drug
David Alvaro, Ph.D.
Pharma's Almanac
PAO-M05-19-NI-012
May 10, 2019
Diabetes
J&J Believes its Diabetes Drug Invokana Is A Game Changer
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M04-19-NI-021
Apr 18, 2019
